A centralised complex venous service model in an NHS hospital

Background/aims Recent evidence supporting the efficacy and safety of deep venous interventions is likely to increase the demand for complex venous services on the NHS. This study aimed to analyse the clinical activity of a tertiary-referral complex venous service model and the estimated costs in an NHS hospital over a period of 1 year. Methods The clinical activity, admission type and treatment cost of all the patients managed by an NHS complex venous service between 1 February 2015 and 31 May 2016 were reviewed. Findings The mean monthly demand for outpatient services for new referrals and follow-ups was 22 and 82.9 respectively. The total number of admissions was 328 (mean of 27.3 admissions per month), with the outpatient cost totaling at £141 888 in 1 year. Conclusions The analysis suggests that the current complex venous service model is feasible and potentially sustainable in an NHS hospital.

Download Full-text

Real-world Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

10.21203/rs.3.rs-59508/v1 ◽

2020 ◽

Author(s):

Jee Hee Yoon ◽

A Ram Hong ◽

Wonsuk Choi ◽

Ji Yong Park ◽

Hee Kyung Kim ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Body Weight ◽

Efficacy And Safety ◽

Tertiary Referral ◽

Tertiary Referral Center ◽

Korean Patients ◽

The Mean

Abstract Background: This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in the real-world clinical practice.Methods: We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center. The primary efficacy endpoint was a change in glycated hemoglobin (HbA1c) between baseline and 6 months. The secondary endpoints were the percentage of patients achieving HbA1c <7.0% or ≤6.5% and the change of body weight at 6 months. Results: At baseline, the mean HbA1c was 8.7 % (8.8% in the add-on to OAD and 8.5% in the add-on to insulin group). The mean adjusted HbA1c at 6 months decreased by −1.13% in the overall patients (p < 0.001), and by −1.36 and −0.74% in the add-on to OAD and add-on to insulin group, respectively. A significant reduction of −2.9 kg in body weight was observed in the overall patients at 6 months (p < 0.001). Approximately 34.8% and 23.2% of patients achieved HbA1c <7.0% and ≤6.5%, respectively. Higher baseline HbA1c and no previous insulin therapy were associated with good response to dulaglutide on multivariate analysis. In subgroup analysis to evaluate the long-term efficacy of dulaglutide (n=82), the mean adjusted HbA1c decreased by −0.86% from baseline to 12 months (p < 0.001). Mild gastrointestinal issues (23.2%) were the most frequently observed adverse events.Conclusions: Dulaglutide is an effective and durable treatment option as add-on to OAD and basal insulin therapy in Korean patients with T2DM.

Download Full-text

OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjz203.023 ◽

2020 ◽

Vol 14 (Supplement_1) ◽

pp. S021-S022 ◽

Cited By ~ 3

Author(s):

S Ben-Horin ◽

J Leszczyszyn ◽

R Dudkowiak ◽

A Lahat ◽

B Gawdis-Wojnarska ◽

...

Keyword(s):

Ulcerative Colitis ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Treatment Options ◽

Maintenance Phase ◽

Mucosal Healing ◽

Comparable Efficacy ◽

Clinical Activity ◽

Efficacy And Safety ◽

The Mean

Abstract Background Two randomised controlled trials of a novel subcutaneous (SC) formulation of infliximab in patients with active rheumatoid arthritis1 and in patients with active Crohn’s disease (CD) and ulcerative colitis (UC)2 confirmed comparable clinical efficacy and safety of CT-P13 SC with CT-P13 intravenous (IV) up to Week 30. We now present the efficacy, pharmacokinetics (PK) and safety of CT-P13 SC over 1-year in the active CD and UC trial, including the outcomes of switching from CT-P13 IV to CT-P13 SC. Methods After loading doses of IV 5 mg/kg at Weeks 0 and 2, patients were randomised at Week 6 to receive either SC 120 mg (<80 kg) or 240 mg (≥80 kg) every 2 weeks (SC arm), or continued on IV 5 mg/kg every 8 weeks (IV arm). From Week 30, IV 5 mg/kg was switched to either SC 120 or 240 mg based on the patients’ body weight at Week 30. Patients who initially responded but experienced loss-of-response at Week 30 or beyond, were dose-escalated to SC 240 mg every 2 weeks. Results A total of 131 patients were randomised (66 to the SC arm and 65 to the IV arm); of whom, 105 (80.2%) patients completed the Week 54 visit (55 in the SC arm and 50 in the IV arm). The mean CDAI and partial Mayo scores decreased over time in the 2 arms until Week 30 and comparable improvement in clinical activity was observed at Week 54 after switching the remaining IV patients to SC (Figure 1 and 2). The rates of clinical response and remission were also maintained at Week 54 and the rate of mucosal healing in combined CD and UC was further improved at Week 54 (Table 1). The mean pre-dose serum concentrations in the IV arm increased to a similar level to SC arm after switching and maintained consistent levels until Week 54 (Figure 3). The safety profiles during the maintenance phase and on or after Week 30 were generally comparable between the 2 arms (Table 1). All of the localised injection site reactions were grade 1 or 2 in intensity and majority of patients recovered without any treatments. Conclusion These results of CT-P13 SC 1-year study in active CD and UC show comparable efficacy and safety of the SC and IV formulations, which were not affected by a switch of IV patients to SC route. The PK as manifested by trough concentrations of the drug, increased after switching from IV to SC. These observations support the first infliximab SC formulation as a viable therapeutic agent to expand patients’ treatment options. References

Download Full-text

Efficacy and Safety of Oral Ivermectin and Topical Permethrin in the Treatment of Scabies

TAJ Journal of Teachers Association ◽

10.3329/taj.v33i1.49824 ◽

2020 ◽

Vol 33 (1) ◽

pp. 41-47

Author(s):

Mohsena Akhter ◽

Ishrat Bhuiyan ◽

Zulfiqer Hossain Khan ◽

Mahfuza Akhter ◽

Gulam Kazem Ali Ahmad ◽

...

Keyword(s):

Skin Diseases ◽

Close Contact ◽

Randomized Study ◽

Sarcoptes Scabiei ◽

Efficacy And Safety ◽

Common Skin ◽

Group A ◽

The Mean ◽

The Difference ◽

Group B

Background: Scabies is one of the most common skin diseases in our country. It is caused by the mite Sarcoptes scabiei var hominis, which is an ecto-parasite infesting the epidermis. Scabies is highly contagious. Prevalence is high in congested or densely populated areas. Individuals with close contact with an affected person should be treated with scabicidal which is available in both oral and topical formulations. The only oral but highly effective scabicidal known to date is Ivermectin. Amongst topical preparations, Permethrin 5 % cream is the treatment of choice. Objective: To evaluate the efficacy & safety of oral Ivermectin compared to topical Permethrin in the treatment of scabies. Methodology: This prospective, non-randomized study was conducted at the out-patient department of Dermatology and Venereology of Shaheed Suhrawardy Medical College & Hospital over a period of 6 months, from August 2016 to January 2017. The study population consisted of one hundred patients having scabies, enrolled according to inclusion criteria. They were divided into two groups. group A was subjected to oral Ivermectin and the group B to Permethrin 5% cream. Patients were followed up on day 7 and 14 for assessment of efficacy and safety. Result: The mean scoring with SD in group A (Ivermectin) and group B (Permethrin) were 8.26 ± 2.22 and 7.59 ± 2.01 respectively at the time of observation. The difference between the mean score of the two group is not significant (p=0.117) the mean scoring with SD in group A and group B were 4.54 ± 2.05 and 1.64 ± 1.84 respectively at 7thdays. The difference between the mean score of the two group is significant (p<0.001). The mean scoring with SD in group A and group B were 2.68± 2.35 and .36± 1.10 respectively at 14th day difference between the mean score of the group is significant (p<0.001). Conclusion: Topical application of permethrin 5% cream is more effective and safer than oral Ivermectin in the treatment of scabies. TAJ 2020; 33(1): 41-47

Download Full-text

A multicenter prospective hospital-based cohort study on the efficacy and safety of pitavastatin.

Current Diabetes Reviews ◽

10.2174/1573399817666201228164243 ◽

2020 ◽

Vol 17 ◽

Author(s):

Abdullah Shehab ◽

Asim Ahmed Elnour ◽

Akshaya Srikanth Bhagavathula ◽

Joseph Pulavelil Kurian ◽

Gazi Hassan ◽

...

Keyword(s):

Cohort Study ◽

Adverse Events ◽

United Arab Emirates ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Low Density ◽

Efficacy And Safety ◽

Onset Diabetes ◽

The Mean ◽

New Onset

Aims: We aim to investigate the efficacy and safety of pitavastatin 4 mg in a population of people living in the United Arab Emirates (UAE). Background: Pitavastatin is a member of the HMG-CoA reductase inhibitors family which was approved for use in adult subjects with primary hyperlipidemia or mixed dyslipidemia. To date, no published studies have assessed the efficacy and safety of pitavastatin in the United Arab Emirates. Objective: The main objective of the current study was to investigate the efficacy and safety of pitavastatin in subjects with dyslipidemia for primary prevention of cardiovascular diseases based on total cardiovascular risk. Methods: This was a multicentre (four private hospitals) prospective cohort study to analyze data on the use of pitavastatin for dyslipidemia in adult outpatients in Abu Dhabi and Dubai emirates, United Arab Emirates. We have followed-up the clinical profiles of subjects in four hospitals for six-weeks during the period from June 2015 to June 2017. Efficacy was based on the evaluation of the mean (± standard deviation) change in low-density lipoprotein cholesterol between baseline and week six after the initiation of pitavastatin therapy. Safety was reported as the incidence of adverse events occurred with the use of pitavastatin and the development of new-onset diabetes. Results: A total of 400 subjects who were receiving pitavastatin 4 mg were included. The mean age of subjects was 50.7 ±10.8 years, of these 79.0% were males. At the baseline, the mean level of total cholesterol was 185.4 ±41.5 mg/dL, low density lipoprotein was 154.9 ±48.55 mg/dL, high-density lipoprotein cholesterol was 40.5 ±11.23 mg/dL and fasting blood glucose was 115.0 (±16.63) mg/dl. At the end of six weeks, low density lipoprotein levels significantly decreased to 112.09 ±41.90 mg/dl (standard mean difference [SMD] (-42.8%), 95% CI: -42.88 [-49.17 to -36.58] mg/dl, P <0.001), while high density lipoprotein levels improved (SMD, 95% CI: 1.77% [0.25 to 3.28] mg/dl, P <0.022). There were 55 subjects (13.7%) reported various adverse events such as myalgia (7.5%), sleep disorders (2.5%), and myopathy (2.2%). Furthermore, 4 (1.0%) have had developed new-onset diabetes post six-weeks of initiation of pitavastatin therapy. Conclusion: Pitavastatin 4 mg had howed robust efficacy in reducing LDL-C levels and improving HDL-C levels in subjects with dyslipidemias. The use of pitavastatin was associated with a low discontinuation rate, fewer adverse events, and very limited cases of new-onset diabetes.

Download Full-text

The efficacy and safety of hybrid ablations for atrial fibrillation, assessed using implantable ECG recorders and sequential magnetic resonance imaging

European Heart Journal ◽

10.1093/ehjci/ehaa946.0627 ◽

2020 ◽

Vol 41 (Supplement_2) ◽

Author(s):

P Osmancik ◽

D Herman ◽

P Kacer ◽

V Rizov ◽

J Vesela ◽

...

Keyword(s):

Rate Control ◽

Rhythm Control ◽

Brain Lesions ◽

Funding Source ◽

Efficacy And Safety ◽

Resonance Imaging ◽

Ischemic Brain ◽

The Mean ◽

Hybrid Ablation ◽

Control Survival

Abstract Background Treatment strategies for patients with non-paroxysmal atrial fibrillation (AF) still do not provide satisfactory results. In pursuit of better results, other approaches, such as the hybrid ablation (i.e., thoracoscopic epicardial ablation followed by catheter ablation), have been used. The accurate data regarding the efficacy and safety of the procedure are still limited. Purpose To determine the procedural safety, and the mid-term efficacy of hybrid ablation. Methods Patients with non-paroxysmal AF were included. They underwent thoracoscopic, off-pump ablation using the COBRA Fusion radiofrequency system, followed by a percutaneous catheter ablation (2.6±1.0 mo after surgery). Sequential cerebral magnetic resonance imaging (MRI) was done (1 day before and 3–5 days after surgery) to look for new ischemic lesions in the brain. Implantable loop recorders (ILR) were implanted 1–3 days after the thoracoscopic procedure. Rhythm outcomes were defined as (1) AF-free OFF survival (i.e., no single episode of AF or atrial tachycardia (AT) lasting >30 sec as assessed using ILR, remaining OFF anti-arrhythmic drugs (AADs) and without a redo ablation or cardioversion), (2) AF-free ON survival (i.e., recurrence of AF or AT, however, AF freedom with no more AF/AT episodes >30 sec was achieved through re-initiation AADs, re-ablation, or cardioversion), and (3) rhythm control survival (repeated self-terminated paroxysms of AF/AT despite AADs, re-ablation, or cardioversion). Rate control strategy (i.e. the presence of AF with no more attempts for SR reinitiation) was considered as failure of the procedure. Results Sixty patients were enrolled, 37 (62%) were men, the mean age was 62.6±10.5 years, 29 (48%) with long-standing persistent AF. Thoracoscopic ablation was successfully performed in 56 (93.3%) patients, and significant complications occurred in 7 (11.8%) patients. Fifty-three patients (88.3%) underwent a pre- and 47 underwent a control postoperative cerebral MRI. Chronic ischemic brain lesions were present in 36 (68%) patients on the pre-operative MRI. New ischemic brain lesions on the post-operative MRI were seen in 19 (40%) patients, 18 of whom were without neurological symptoms, 1 patient had a manifest stroke. Catheter ablations were carried out in all 60 patients without complications. The mean follow-up was 22.9±10.3 months. AF-free OFF survival was present in 53.4% at 1 and in 41.5% at 2 years. AF-free ON survival was present in 72% at 1 year and 62% at 2 years. Rhythm control survival was present in 91% at 1 year and 89% at 2 years. Only 9%, or 11% of patients were on rate control at 1 and 2 years, resp. Conclusions Hybrid ablation presents an effective treatment strategy for patients with non-paroxysmal AF. The thoracoscopic part of the hybrid ablation procedure is accompanied by a high risk of silent cerebral ischemia, which should be considered in patients referred to this procedure. Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): Research grant of the Ministry of Health of the Czech Republic, Nr. 16-32478A

Download Full-text

Efficacy and safety of radiofrequency ablation for benign thyroid nodules in patients with previous thyroid lobectomy

BMC Medical Imaging ◽

10.1186/s12880-021-00577-5 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Lin Yan ◽

Mingbo Zhang ◽

Fang Xie ◽

Jun Ma ◽

Jing Xiao ◽

...

Keyword(s):

Radiofrequency Ablation ◽

Symptom Score ◽

Thyroid Function ◽

Thyroid Nodules ◽

Efficacy And Safety ◽

Thyroid Lobectomy ◽

The Mean ◽

Benign Thyroid Nodules ◽

Benign Thyroid

Abstract Background Radiofrequency ablation (RFA) is recommended for the treatment of benign thyroid nodules. However, data on the clinical role of RFA for benign thyroid nodules in patients with history of thyroid lobectomy are insufficient. The purpose of this study was to evaluate the efficacy and safety of radiofrequency ablation (RFA) for benign thyroid nodules in patients who had previously undergoing thyroid lobectomy. Methods From May 2015 to October 2018, a total of 20 patients (19 females, 1 male, mean age 49.50 ± 14.26 years, range 22–74 years) with 20 benign thyroid nodules (mean volume 15.04 ± 21.17 ml, range 0.40–69.67 ml) who had undergone previous thyroid lobectomy were included in this retrospective study. Patients were followed up at 3, 6, 12 months after RFA and every 12 months thereafter by ultrasound, clinical evaluation and thyroid function. Volume, volume reduction rate (VRR), symptom score and cosmetic score were evaluated. Results During the mean follow-up time of 21.24 ± 16.41 months, the mean nodule volume decreased significantly from 15.04 ± 21.17 ml to 1.29 ± 1.17 ml (P = 0.018) with a mean VRR of 85.41 ± 12.17%. Therapeutic success was achieved in a single session for all thyroid nodules. The symptom score (P = 0.001) and cosmetic score (P = 0.001) were both significantly reduced at the last follow-up. The levels of free triiodothyronine (fT3), free thyroxine (fT4) and thyroid stimulating hormone were not significantly different at the last follow-up from those prior to treatment (all P > 0.05). No life-threatening complications or sequelae occurred after RFA. Conclusions As a minimally invasive modality, RFA was a safe, effective, and thyroid function-preserving option for patients with symptomatic benign thyroid nodules after a previous lobectomy.

Download Full-text

Evaluation of extraocular muscles in patients with thyroid associated ophthalmopathy using apparent diffusion coefficient measured by magnetic resonance imaging before and after radiation therapy

Acta Radiologica ◽

10.1177/02841851211034042 ◽

2021 ◽

pp. 028418512110340

Author(s):

Wu Yu ◽

Lao Zheng ◽

Zhang Shuo ◽

Liu Xingtong ◽

Jiang Mengda ◽

...

Keyword(s):

Diffusion Coefficient ◽

Radiation Therapy ◽

Apparent Diffusion Coefficient ◽

Extraocular Muscles ◽

Clinical Activity ◽

Inferior Rectus ◽

Thyroid Associated Ophthalmopathy ◽

Before And After ◽

Apparent Diffusion ◽

The Mean

Background Thyroid-associated ophthalmopathy (TAO) is an autoimmune orbital disease characterized by edema of extraocular muscles (EOMs). Purpose To characterize the inflammation of EOMs in patients with TAO before and after radiation therapy using apparent diffusion coefficient (ADC) and to analyze the correlation between ADC and clinical activity of TAO. Material and Methods The ADCs of superior rectus (SR), inferior rectus (IR), medial rectus (MR), and lateral rectus (LR) muscles were measured in 52 eyes of 26 patients with TAO before and three months after orbital radiation therapy. In addition, 38 eyes of 20 healthy volunteers were included. The clinical activity score (CAS) was evaluated. The ADC maps were reconstructed and measured on the coronal diffusion-weighted imaging (DWI) sequence and calculated in mm2/s. Results The mean ADCs of EOMs before treatment were 1.42 ± 0.23 in SR, 1.37 ± 0.23 in IR, 1.41 ± 0.21 in MR, and 1.28 ± 0.25 in LR. The mean ADCs after treatment were 1.27 ± 0.18, 1.22 ± 0.26, 1.30 ± 0.22, and 1.15 ± 0.21, respectively. The ADCs were significantly decreased after treatment (all P < 0.001). The ADCs of patients with TAO were significantly higher than those of controls. There was a statistically significant correlation between the mean ADCs and the CAS in each patient with TAO both before and after treatment (before: r = 0.520; P < 0.001; after: r = 0.625; P < 0.001). Conclusion The ADC values of EOMs can be exploited as a quantitative indicator to evaluate the clinical activity and monitor the therapeutic responses of patients with TAO.

Download Full-text

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C

Terapevticheskii arkhiv ◽

10.26442/00403660.2019.08.000384 ◽

2019 ◽

Vol 91 (8) ◽

pp. 67-74

Author(s):

E A Klimova ◽

E Z Burnevich ◽

V P Chulanov ◽

D A Gusev ◽

O O Znoyko ◽

...

Keyword(s):

Hepatitis C ◽

Efficacy And Safety ◽

Hcv Genotype ◽

Genotype 1B ◽

Safety Population ◽

Viral Hepatitis C ◽

Treatment Naïve ◽

The Mean ◽

Almost All ◽

Direct Acting

Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods. The study enrolled adult patients with HCV genotype 1b infection without demonstrated NS5A resistance - associated substitutions Y93C/H/N/S and/or L31F/M/V/I. Patients were treated with narlaprevir 200 mg QD, ritonavir 100 mg QD and daclatasvir 60 mg QD. Treatment duration was 12 weeks. Proportion of patients achieving sustained virological response 12 weeks after treatment (SVR12) was the primary efficacy endpoint. Results and discussion. In total, 105 (75.0%) patients were treatment with the study combination. Patients’ age varied from 21 to 69 years, the mean age being 43.2±10.9 years. There were slightly more women (55.2%), and 69 patients (65.7%) had comorbidities. SVR 12 was 89.5% (95% CI 82.0-94.7%). In 10 of 11 patients with treatment failures NS5A resistance - associated substitutions in residues 31 and/or 93 were found, as well as less clinically relevant substitutions L28M, P58S, R30Q, Q62K. Adverse events (AEs) were found in less than one half of patients (45 patients, or 42.9% in the safety population). Almost all recorded AEs were mild to moderate. Conclusion. Efficacy of treatment with a combination of narlaprevir/ritonavir and daclatasvir in treatment - naïve patients with HCV genotype 1b was close to 90%. This combination was found to be safe and well - tolerated.

Download Full-text

A multi-professional approach for transition of care at discharge in hyperglycemic inpatients with covid-19: a single center study

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530322666220104100944 ◽

2022 ◽

Vol 22 ◽

Author(s):

Elena Castellano ◽

Donatella Gaviglio ◽

Micaela Pellegrino ◽

Laura Gianotti ◽

Giampaolo Magro ◽

...

Keyword(s):

Insulin Treatment ◽

Newly Diagnosed ◽

Efficacy And Safety ◽

Glucocorticoid Treatment ◽

Single Center Study ◽

Discharged Patients ◽

The Mean ◽

Glycemic Target ◽

Discharge From Hospital ◽

Drop Outs

Background: The discharge from hospital of insulin-treated hyperglycemic patients is always challenging. This is even more so in patients requiring glucocorticoid treatment, such as those with COVID-19. Patients and method: A retrospective monocentric study of 23 inpatients with newly diagnosed or already known diabetes mellitus (DM) who were naïve to insulin treatment, , and who were hospitalized with COVID-19 in non-critical settings and then discharged. Patients were followed-up for one month after discharge for the management of insulin treatment by a multi-professional team through phone consultations. Results: Insulin prescriptions at discharge were 24.6 ± 14 U/day injected in 2 ± 1.5 daily shots. A mean of three phone consultations were required. One month later, the mean insulin reduction was 1.5 ± 1.3 shots and 6 ± 5 U/day. All patients reached their glycemic target without hypoglycemic events, drop-outs, or readmissions. Conclusion: This study demonstrates the feasibility, efficacy, and safety of a multi-professional approach through telemedicine for managing DM patients after discharge during COVID-19.

Download Full-text

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ◽

10.3727/096504019x15662966719585 ◽

2020 ◽

Vol 28 (1) ◽

pp. 75-94 ◽

Cited By ~ 2

Author(s):

Junhui Sun ◽

Guanhui Zhou ◽

Xiaoxi Xie ◽

Wenjiang Gu ◽

Jing Huang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Liver Cancer ◽

Portal Vein ◽

Treatment Response ◽

Transarterial Chemoembolization ◽

Efficacy And Safety ◽

Portal Vein Invasion ◽

Drug Eluting Beads ◽

Drug Eluting ◽

The Mean

The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response rate (ORR) were 22.9%, 60.7%, and 83.6%, respectively. The mean PFS was 362 (95% CI: 34.9‐375) days, the 6-month PFS rate was 89.4 ± 2.1%, while the mean OS was 380 (95% CI: 370‐389) days, and the 6-month OS rate was 94.4 ± 1.7%. Multivariate logistic regression revealed that portal vein invasion (p = 0.011) was an independent predictor of worse clinical response. Portal vein invasion (p = 0.040), previous cTACE treatment (p = 0.030), as well as abnormal serum creatinine level (BCr) (p = 0.017) were independent factors that predicted worse ORR. In terms of survival, higher Barcelona Clinic Liver Cancer (BCLC) stage (p = 0.029) predicted for worse PFS, and abnormal albumin (ALB) (p = 0.011) and total serum bilirubin (TBIL) (p = 0.009) predicted for worse OS. The number of patients with abnormal albumin, total protein (TP), TBIL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were augmented at 1 week posttreatment and were similar at 1‐3 months compared with baseline. The most common AEs were pain, fever, nausea, and vomiting, and no severe AEs were observed in this study. DEB-TACE was effective and tolerable in treating Chinese HCC patients, and portal vein invasion, previous cTACE treatment, abnormal BCr, ALB, and TBIL appear to be important factors that predict worse clinical outcome.

Download Full-text